Quarterly Financial Results for Q2 2026 – This 10-Q covers Illumina, Inc.'s financial performance for the second quarter ended June 28, 2026, including consolidated statements of operations, balance sheets, and cash flow statements for the six-month period ended June 28, 2026 Product and Service Revenue Segments – The filing contains detailed breakdowns of revenue by product and service…

Our analysis rates this filing NEUTRAL. Illumina presents a balanced risk profile appropriate for a mature, dominant player in a regulated biotech/diagnostics sector. The primary concern is the SomaLogic acquisition integration, which introduces moderate execution risk and balance sheet complexity…

Concern level: ELEVATED (5.2/10). Key factors: SomaLogic acquisition integration risk (severity 6/10) - material capital deployment with execution complexity, goodwill impairment potential if synergies unrealized; Competitive pressure in sequencing market (severity 5/10) - pricing pressure on core business from lower-cost alternatives and new entrants; Regulatory and compliance complexity…

Notable risk changes: SomaLogic Acquisition Completed (January 30, 2026): Illumina completed acquisition of proteomics company, expanding beyond core genomics business. Subsequent event disclosed (July 27, 2026) indicates ongoing transaction-related matters. Material intangible assets recorded suggest significant goodwill and amortizable intangibles on balance sheet.; Product/Service Mix Expansion: Acquisition of…

The model predicts ILMN will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.